7 results about "Synuclein alpha" patented technology

The application discloses genetically engineered ferritin against alpha synuclein, a preparation method and application thereof, and belongs to the technical field of biological medicine and protein engineering. The genetically engineered ferritin is constructed by fusing and expressing NACore polypeptide and human heavy chain ferritin through gene recombination technology, and has alpha synuclein aggregation inhibition activity. The genetically engineered ferritin can specifically combine with the NAC region of alpha synuclein, significantly inhibits the misfolding and aggregation of alpha synuclein, and provides a new drug raw material and treatment strategy for the treatment of Parkinson's disease and other alpha synuclein related neurodegenerative diseases. The genetically engineered ferritin prepared by the application has uniform particle size distribution and stable physicochemical properties. Molecular simulation verifies that the genetically engineered ferritin can efficiently combine with the NAC region of alpha synuclein. ThT fluorescence detection and CCK-8 experiments prove that the genetically engineered ferritin can inhibit the aggregation and fibrosis of alpha synuclein, and lays a solid foundation for the clinical treatment of related diseases.

The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a synuclein alpha (SNCA) gene. The SNCA RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an SNCA gene. The SNCA RNAi agents are conjugated to an antigen binding protein that may enable subcutaneous delivery of the RNAi agents by facilitating crossing of the blood brain barrier (BBB). Pharmaceutical compositions that include one or more SNCA RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described SNCA RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of SNCA gene expression and a reduction in SNCA activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including Parkinson's Disease.

The present invention relates to methods of identifying subjects suffering from Multiple System Atrophy (MSA) or Parkinson's Disease (PD). The method comprises subjecting a biological sample obtained from a subject to a seeded aggregation assay or a sequence of seeded aggregation assays. The invention also further provides methods of treating the identified MSA patient or the PD patient with compounds capable of inhibiting alpha synuclein aggregation.

The present invention relates to immunogenic compositions that can be employed for the prevention, alleviation or treatment of a condition associated with diseases, disorders and abnormalities associated with alpha synuclein (alpha synuclein, α-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates including, but not limited to, Lewy bodies and / or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) ("pure" Lewy body dementia), Parkinson's disease dementia (PDD)), or Diffuse Lewy Body Disease.

Methods and kits are provided for amplifying and detecting αS proteins from samples, for example, from patients having Parkinson's Disease. For example, a method for determining a presence of a soluble, misfolded αS protein may include: contacting the sample with a monomeric, folded αS protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded αS protein; incubating the incubation mixture effective to cause misfolding and / or aggregation of at least a portion of the monomeric, folded αS protein in the presence of the soluble, misfolded αS protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded αS aggregate present; and determining the presence of the soluble, misfolded αS protein in the sample by detecting at least a portion of the soluble, misfolded αS protein.

The application discloses a method for producing recombinant human proteins in industrial microorganisms, comprising the following steps: introducing a gene coding alpha synuclein into corynebacterium glutamicum by genetic engineering technology to realize expression of the alpha synuclein; and isolating the alpha synuclein in liquid droplet-like membraneless organelles by liquid-liquid phase separation technology to further improve protein yield. Compared with the most widely used Escherichia coli expression system, the method has the following advantages: the method uses corynebacterium glutamicum as a new type of chassis cell, and overcomes problems such as endotoxin pollution and insoluble inclusion body formation in a traditional Escherichia coli expression system; the method significantly improves the yield of alpha synuclein by applying liquid-liquid phase separation technology; the method is not only suitable for the production of alpha synuclein, but also can be popularized to other difficult-to-express proteins, and provides a new technical path for the field of biological pharmacy.